Markets
Akebia Therapeutics, Inc. (AKBA)
AKBANASDAQ-CMBiotechnology: Pharmaceutical Preparations
$0.5332
+0.1323 (+33.00%) today
Closed, Nov 9, 4:00 PM ET
+33.00% 1D
- Market cap
- $147.94m
- P/E
- –
- EPS, last 4 quarters
- $-0.1400
- Dividend yield
- –
- Day range
- –
- 52-week range
- $0.3612 to $2.07
- Average volume
- 8.14m
- Previous close
- $0.4009
Analysts
5 coveringBuy4 buy, 1 hold, 0 sell
Targets a year out average $3.88, +627.7% from here
$3.00now $0.5332$4.50
Earnings
next estimate $-0.0400Next report
Dec 2025
-66.7%
Mar 2026
-200.0%
Jun 2026
+33.3%
Sep 2026
-33.3%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | $58.77m | $57.62m | $53.54m | $49.13m |
| Gross profit | $49.38m | $45.09m | $41.25m | $38.70m |
| Operating income | $4.45m | -$8.55m | -$4.70m | -$6.33m |
| Net income | $540.0k | -$12.24m | -$9.05m | -$8.91m |
Last four quarters: revenue $219.06m, margin -13.5%, free cash flow $40.26m
News
8 latest- Akebia (AKBA) Q3 2026 Earnings Call TranscriptThe Motley Fool · 3 days ago
- Akebia Therapeutics Reports Third Quarter 2026 Financial ResultsFintel · 4 days ago
- What Akebia Therapeutics (AKBA) Said on Its Q3 Earnings CallMarketBeat · 4 days ago
- Akebia Therapeutics (AKBA) Reports Q3 Loss, Misses Revenue EstimatesZacks · 5 days ago
- Akebia Therapeutics, Inc. Receives Nasdaq Minimum Bid Price Deficiency NoticeFintel · Oct 23, 2026
- Akebia Doses First Patient In Phase 2 Trial Of Ebribafusp For Rare Kidney Diseases RTTNews · Sep 14, 2026
- WestPark Capital Initiates Coverage of Akebia Therapeutics with Buy RatingFintel · Sep 8, 2026
- Akebia Therapeutics Q2 Earnings Call HighlightsMarketBeat · Aug 5, 2026
The company
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Waltham, Massachusetts .
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- akebia.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.